More on MYGN

- Summary
- Chart
- Profile
- Historical


- Earnings (+100.0% Growth)
- Ratings (2.9 Score)
- Holders


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (2/27/24 *Est.)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

MYGN Cash Flow Statement

Click line-items for a historical chart and %
Cash flows from operating activities:
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
Loss on disposition of assets -200K
Share-based compensation expense 7.8M
Bad debt expense 7.2M
Non-cash expense related to in-process research and development technology
Unrecognized tax benefits 400K
Excess tax benefit from share-based compensation
(Gain) loss on sale of marketable investment securities
Changes in operating assets and liabilities:
Prepaid expenses 7.8M
Trade accounts receivable -5.9M
Other receivables -1.8M
Inventory -13M
Deferred income taxes 3.2M
Accounts payable -5M
Accrued liabilities -9.5M
Deferred revenue -1M
Net cash provided by operating activities
Cash flows from investing activities:
Capital expenditures for equipment and leasehold improvements -1.5M
Acquisition of Rules-Based Medicine, Inc. (see Note 14), net of cash acquired -213M
Purchase of in-process research and development technology
Purchase of other assets
Proceeds from sale of intellectual property
Purchases of marketable investment securities
Proceeds from maturities and sales marketable investment securities 88.7M
Net cash used in investing activities
Cash flows from financing activities:
Cash and cash equivalents contributed to Myriad Pharmaceuticals, Inc.
Net proceeds from common stock issued under share-based compensation plans
Excess tax benefit from share-based compensation
Repurchase and retirement of common stock -21.3M
Net cash provided by financing activities
Effect of foreign exchange rates on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents 18.4M
Cash and cash equivalents at beginning of year 68.5M
Cash and cash equivalents at end of year 86.9M
Supplemental cash flow information:
Cash paid during the year for income taxes
Non-cash investing and financing activities:
Fair value adjustment on marketable investment securities recorded to stockholders' equity
Transfer of assets, net of liabilities to Myriad Pharmaceuticals, Inc.